Lindsley A, Lugogo N, Reeh K, Spahn J, Parnes J
J Asthma Allergy. 2025; 18():33-57.
PMID: 39830595
PMC: 11742565.
DOI: 10.2147/JAA.S496630.
Gyawali B, Georas S, Khurana S
Eur Respir Rev. 2025; 34(175).
PMID: 39778920
PMC: 11707604.
DOI: 10.1183/16000617.0088-2024.
Brightling C, Marone G, Aegerter H, Chanez P, Heffler E, Pavord I
Eur Respir Rev. 2024; 33(174.
PMID: 39694589
PMC: 11653196.
DOI: 10.1183/16000617.0221-2024.
Israel E, Castro M, Ambrose C, Llanos J, Molfino N, Martin N
ERJ Open Res. 2024; 10(6).
PMID: 39588080
PMC: 11587167.
DOI: 10.1183/23120541.00164-2024.
Lombardi C, Cottini M, Bosi A, Menzella F
J Int Med Res. 2024; 52(11):3000605241297532.
PMID: 39552062
PMC: 11571243.
DOI: 10.1177/03000605241297532.
Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets.
Hansi R, Ranjbar M, Whetstone C, Gauvreau G
Biomedicines. 2024; 12(10).
PMID: 39457624
PMC: 11505104.
DOI: 10.3390/biomedicines12102312.
Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles.
Caminati M, Vatrella A, Rogliani P, Carpagnano E, Spanevello A, Senna G
Respir Res. 2024; 25(1):367.
PMID: 39385131
PMC: 11465883.
DOI: 10.1186/s12931-024-02998-6.
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
Wechsler M, Brusselle G, Virchow J, Bourdin A, Kostikas K, Llanos J
Eur Respir J. 2024; 64(6).
PMID: 39326921
PMC: 11618813.
DOI: 10.1183/13993003.00316-2024.
Choosing the Right Biologic for the Right Patient With Severe Asthma.
Couillard S, Jackson D, Pavord I, Wechsler M
Chest. 2024; 167(2):330-342.
PMID: 39245321
PMC: 11867899.
DOI: 10.1016/j.chest.2024.08.045.
Tezepelumab: patient selection and place in therapy in severe asthma.
Menzella F, Munari S, Corsi L, Tonin S, Cestaro W, Ballarin A
J Int Med Res. 2024; 52(4):3000605241246740.
PMID: 38676539
PMC: 11056094.
DOI: 10.1177/03000605241246740.
Airway remodelling in asthma and the epithelium: on the edge of a new era.
Varricchi G, Brightling C, Grainge C, Lambrecht B, Chanez P
Eur Respir J. 2024; 63(4).
PMID: 38609094
PMC: 11024394.
DOI: 10.1183/13993003.01619-2023.
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Panettieri Jr R, Lugogo N, Corren J, Ambrose C
J Asthma Allergy. 2024; 17:219-236.
PMID: 38524099
PMC: 10960583.
DOI: 10.2147/JAA.S342391.
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
Russell R, Boulet L, Brightling C, Pavord I, Porsbjerg C, Dorscheid D
Eur Respir J. 2024; 63(4).
PMID: 38453256
PMC: 10991852.
DOI: 10.1183/13993003.01397-2023.
Human macrophage migration inhibitory factor potentiates mesenchymal stromal cell efficacy in a clinically relevant model of allergic asthma.
Hawthorne I, Dunbar H, Tunstead C, Schorpp T, Weiss D, Rolandsson Enes S
Mol Ther. 2023; 31(11):3243-3258.
PMID: 37735872
PMC: 10638061.
DOI: 10.1016/j.ymthe.2023.09.013.
Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
Bernstein J, Llanos J, Hunter G, Martin N, Ambrose C
Adv Ther. 2023; 40(11):4721-4740.
PMID: 37698716
PMC: 10567947.
DOI: 10.1007/s12325-023-02647-2.
Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma.
Plaza V, Canete C, Domingo C, Martinez Rivera C, Munoz X
Open Respir Arch. 2023; 5(2):100231.
PMID: 37496871
PMC: 10369521.
DOI: 10.1016/j.opresp.2022.100231.
Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review.
Spahn J, Brightling C, OByrne P, Simpson L, Molfino N, Ambrose C
J Asthma Allergy. 2023; 16:755-774.
PMID: 37496824
PMC: 10368134.
DOI: 10.2147/JAA.S410592.
T-helper cells and their cytokines in pathogenesis and treatment of asthma.
Ji T, Li H
Front Immunol. 2023; 14:1149203.
PMID: 37377958
PMC: 10291091.
DOI: 10.3389/fimmu.2023.1149203.
Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.
Korn S, Cook B, Simpson L, Llanos J, Ambrose C
Adv Ther. 2023; 40(7):2944-2964.
PMID: 37233876
PMC: 10272272.
DOI: 10.1007/s12325-023-02514-0.
The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis.
Wu Y, Huang M, Zhong J, Lu Y, Gan K, Yang R
Front Immunol. 2023; 14:1089710.
PMID: 37114057
PMC: 10126252.
DOI: 10.3389/fimmu.2023.1089710.
